{
  "nct_id": "NCT03220217",
  "study_title": "To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)",
  "search_date": "2025-07-15T14:06:15.810726",
  "publications_found": 1,
  "publications": [
    {
      "pmid": "34487283",
      "title": "Miller CG, Gronbaek H, Virgolini I, Kjaer A, Terve P, Bahri S, Iversen P, Svirydenka H, Rohban T, Mc...",
      "authors": [],
      "journal": "From Clinical Trial Data",
      "year": "N/A",
      "doi": null,
      "abstract": "Miller CG, Gronbaek H, Virgolini I, Kjaer A, Terve P, Bahri S, Iversen P, Svirydenka H, Rohban T, McEwan S. A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial. EJNMMI Res. 2021 Sep 6;11(1):84. doi: 10.1186/s13550-021-00819-1.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34487283/",
      "source": "study_data"
    }
  ]
}